Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Rain Oncology Inc. (RAIN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
08/17/2023 SC 13D/A BIOTECHNOLOGY VALUE FUND L P reports a 12.8% stake in Rain Oncology Inc.
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Investor Contact"
06/01/2023 SC 13D TANG CAPITAL PARTNERS LP reports a 14.1% stake in Rain Oncology Inc.
05/11/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/11/2023 8-K Quarterly results
Docs: "RAIN ONCOLOGY INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 16,677 $ 13,555 General and administrative 5,066 3,895 Total operating expenses 21,743 17,450 Loss from operations Other income: Interest income 1,259 56 Total other income 1,259 56 Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average shares used in computing net loss per share, basic and diluted 36,339,851 26,511,743 SUMMARY CONDENSED CONSOLIDATED BALANCE SHEET DATA"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 SC 13G/A Flynn James E reports a 0% stake in Rain Oncology Inc.
04/19/2023 ARS Form ARS - Annual Report to Security Holders:
04/19/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/19/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/09/2023 8-K Quarterly results
Docs: "Three Months Ended December 31, Twelve Months Ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 19,078 $ 14,672 $ 61,400 $ 40,773 General and administrative 4,479 3,405 15,736 10,739 Total operating expenses 23,557 18,077 77,136 51,512 Loss from operations Other income: Interest and other income 882 94 1,415 120 Total other income 882 94 1,415 120 Net loss before income tax expense Income tax expense Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average shares used to compute net loss per share, basic and diluted 32,288,083 26,470,600 27,985,446 19,405,833 SUMMARY CONSOLIDATED BALANCE SHEET DATA"
02/14/2023 SC 13G Samsara BioCapital, L.P. reports a 9.1% stake in Rain Oncology Inc.
02/14/2023 SC 13G/A Cormorant Global Healthcare Master Fund, LP reports a 10% stake in Rain Oncology Inc.
02/14/2023 SC 13G/A PERCEPTIVE ADVISORS LLC reports a 9.3% stake in Rain Oncology Inc.
02/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "R A I N O N C O L O G Y I N C . 2 Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including statements concerning the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results, the timing and focus of our ongoing and future preclinical studies and clinical trials, the design of those studies and trials, and the reporting of data from those studies and trials, the timing for enrollment of trials, our plan..."
01/30/2023 SC 13G ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 8.1% stake in Rain Oncology, Inc.
01/23/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact"
12/29/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ...
Docs: "CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RAIN THERAPEUTICS INC.",
"SECOND AMENDED AND RESTATED BYLAWS OF RAIN ONCOLOGY INC.",
"Investor Contact"
11/18/2022 SC 13G Flynn James E reports a 10% stake in Rain Therapeutics, Inc.
11/08/2022 SC 13D/A Boxer Capital, LLC reports a 10% stake in Rain Therapeutics Inc.
11/04/2022 8-K Quarterly results
11/03/2022 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/07/2022 EFFECT Form EFFECT - Notice of Effectiveness:
06/03/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/27/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/06/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/04/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/20/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/20/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/03/2022 10-K Annual Report for the period ended December 31, 2021
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy